MESOBLAST Aktie

 

Two experts have presented their case for buying and selling the ASX biotech stock. The post Mesoblast shares: bull vs. bear appeared first on The Motley Fool Australia....

Sales are growing for this biotech. Let's see what it reported today. The post Mesoblast shares push higher on strong sales update appeared first on The Motley Fool Australia....

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided a trading update, together with a comprehensive operational overview, as part of the Chief Executive's Annual General Meeting (AGM) address....

Analysts have given their verdicts on these shares. The post Should you buy Mesoblast, Paladin Energy, and Xero shares? appeared first on The Motley Fool Australia....

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high rate of non-responsiveness to therapies in adults with severe acute graft versus host disease (aGvHD) who fail corticosteroids, and the high mortality in these patients, Mesoblast and the United States National Institutes of Health (NIH)-funded Blood and Marrow Transplant Clinical Trials Network (BMT CTN) will collaborate on a pivotal trial of Ryoncil® (remestemcel-L-rknd) as part of first-line regimen in adults with severe aGvHD refractory to corticosteroids (SR-aGvHD). The BMT CTN is a body representing U.S. centers responsible for performing approximately 80% of all U.S. allogeneic BMTs....

These shares have been hit with sell ratings. But why? The post Brokers say Mesoblast, NAB, and Pilbara Minerals shares are sells appeared first on The Motley Fool Australia....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company's transition to a fully integrated commercial organization it has appointed James M. O'Brien as its US-based Chief Financial Officer (CFO). Jim has extensive experience in all aspects of financial management and planning having spent the majority of his career with multi-national public and private companies in the life sciences, biotechnology, and pharmaceutical industries....

Find out if the company is set to experience more growth. The post Mesoblast shares surge 60% in a year. Have investors missed the boat? appeared first on The Motley Fool Australia....

After losing some value lately, a hammer chart pattern has been formed for Mesoblast Limited (MESO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term....

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the U.S. Food & Drug Administration (FDA) has scheduled a meeting in early December to discuss Mesoblast's data on opioid reduction and cessation from its first Phase 3 study (MSB-DR003) of rexlemestrocel-L in patients with chronic low back pain (CLBP)....

Mesoblast Limited (MESO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

Mesoblast shares are in the spotlight after strong revenue growth from Ryoncil® boosted confidence in the company's outlook. The post Mesoblast earnings: surging cell therapy revenues highlight growth appeared first on The Motley Fool Australia....

This biotech could be high risk, high reward picks according to Bell Potter. The post Why Mesoblast shares could rise 40% in a year appeared first on The Motley Fool Australia....

These shares are having a good time on hump day. But why? The post Why DroneShield, James Hardie, Lifestyle Communities, and Mesoblast shares are storming higher appeared first on The Motley Fool Australia....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

These shares are having a better day than most on Tuesday. But why? The post Why DroneShield, Greatland Resources, Mesoblast, and Web Travel shares are storming higher today appeared first on The Motley Fool Australia....

Mesoblast (ASX:MSB) jumped around +8% in morning trades to $2.80 a pop…...

Investors are piling into Mesoblast shares today. But why? The post Why did the Mesoblast share price just rocket 13%? appeared first on The Motley Fool Australia....